16 September 2026 editorial review · Item
Low-dose anti-thymocyte globulin (ATG): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: MELD-ATG paper verified doses 0.5/2.5 mg/kg, serum sickness 32%/82%, cytokine release 24%/33%. Updated ASCEND to recruiting on 9 September, n 60, Nov 2029 estimated completion; removed old registry/site disagreement.
- Registry NCT04291703: TERMINATED; updated 2026-05-07; enrollment 2 (ACTUAL); primary completion 2024-12-17 (ACTUAL); results posted.
- Registry NCT07216391: RECRUITING; updated 2026-09-09; enrollment 60 (ESTIMATED); primary completion 2029-11-30 (ESTIMATED); results not posted in retrieved record.
- Registry NCT02215200: COMPLETED; updated 2020-03-02; enrollment 89 (ACTUAL); primary completion 2017-08 (ACTUAL); results posted.
- Registry NCT04509791: COMPLETED; updated 2025-01-10; enrollment 114 (ACTUAL); primary completion 2024-12-16 (ACTUAL); results not posted in retrieved record.
- Registry NCT00515099: TERMINATED; updated 2017-05-11; enrollment 58 (ACTUAL); primary completion 2012-06 (ACTUAL); results posted.
- Primary publication/regulatory sources checked or consulted: dc18-0494; db19-0057; S0140-6736%2825%2901674-5; S2213-8587%2813%2970065-2; db16-0823; bmjopen-2021-053669; dc15-1419; dbi20-0054.
- Programme/sponsor/conference source boundary: ATG and Teplizumab Comparative Prevention Study (ASCEND T1D) (registry).